Immune Therapeutics (OTCMKTS:IMUN) vs. Vincerx Pharma (NASDAQ:VINC) Critical Analysis

Immune Therapeutics (OTCMKTS:IMUN) and Vincerx Pharma (NASDAQ:VINC) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, earnings, institutional ownership, valuation, dividends and risk.

Earnings & Valuation

This table compares Immune Therapeutics and Vincerx Pharma’s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immune Therapeutics	N/A	N/A	-$3.54 million	N/A	N/A
Vincerx Pharma	N/A	N/A	-$40.16 million	($1.89)	-0.45

Profitability

This table compares Immune Therapeutics and Vincerx Pharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Immune Therapeutics	N/A	N/A	-544.75%
Vincerx Pharma	N/A	-187.73%	-126.26%

Risk & Volatility

Immune Therapeutics has a beta of 0.46, meaning that its share price is 54% less volatile than the S&P 500. Comparatively, Vincerx Pharma has a beta of 1.1, meaning that its share price is 10% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current recommendations for Immune Therapeutics and Vincerx Pharma, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immune Therapeutics	0	0	0	0	N/A
Vincerx Pharma	0	0	1	0	3.00

Vincerx Pharma has a consensus price target of $5.00, indicating a potential upside of 481.46%. Given Vincerx Pharma’s higher possible upside, analysts clearly believe Vincerx Pharma is more favorable than Immune Therapeutics.

Insider and Institutional Ownership

44.0% of Vincerx Pharma shares are held by institutional investors. 50.6% of Immune Therapeutics shares are held by insiders. Comparatively, 22.9% of Vincerx Pharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Vincerx Pharma beats Immune Therapeutics on 5 of the 8 factors compared between the two stocks.

About Immune Therapeutics

Immune Therapeutics, Inc. does not have significant operations. The company was formerly known as TNI BioTech, Inc. and changed its name to Immune Therapeutics, Inc. in October 2014. Immune Therapeutics, Inc. is based in Winter Park, Florida.

About Vincerx Pharma

Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. It is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with hematologic malignancies; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat solid tumors. The company's preclinical stage product candidates include VIP943 and VIP924 for the treatment of hematologic malignancies. Vincerx Pharma, Inc. was founded in 2019 is based in Palo Alto, California.